| Effects of the Neuropeptides Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Peptide in Male Fertility. | Effects of the Neuropeptides Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Peptide in Male Fertility.
Bdeir R, Al-Keilani MS, Khamaiseh K., Free PMC Article | 05/13/2024 |
| Sympathetic System in Wound Healing: Multistage Control in Normal and Diabetic Skin. | Sympathetic System in Wound Healing: Multistage Control in Normal and Diabetic Skin.
Ivanov E, Akhmetshina M, Erdiakov A, Gavrilova S., Free PMC Article | 03/1/2023 |
| Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression. | Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression.
Zhu J, Wang Y, Li J, Das PK, Zhang H, Passang T, Li JM, Nagy T, Gandhi K, Ravindranathan S, Giver CR, Hassan M, Li Y, Antonova AU, Wang S, Roback JD, Waller EK., Free PMC Article | 10/1/2022 |
| Human CD4(+)CD45RA(+) T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide. | Human CD4(+)CD45RA(+) T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide.
Villanueva-Romero R, Cabrera-Martín A, Álvarez-Corrales E, Carrión M, Pérez-García S, Lamana A, Castro-Vázquez D, Martínez C, Gomariz RP, Gutiérrez-Cañas I, Juarranz Y., Free PMC Article | 04/16/2022 |
| Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case-control study. | Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case-control study.
Al-Keilani MS, Almomani BA, Al-Sawalha NA, Al Qawasmeh M, Jaradat SA. | 04/9/2022 |
| Changes in ghrelin, substance P and vasoactive intestinal peptide levels in the gastroduodenal mucosa of patients with morbid obesity. | Changes in ghrelin, substance P and vasoactive intestinal peptide levels in the gastroduodenal mucosa of patients with morbid obesity.
Atas U, Erin N, Tazegul G, Elpek GO, Yildirim B. | 01/29/2022 |
| VIP modulates human macrophages phenotype via FPRL1 via activation of RhoA-GTPase and PLC pathways. | VIP modulates human macrophages phenotype via FPRL1 via activation of RhoA-GTPase and PLC pathways.
Harhous Z, Faour WH, El Zein N. | 10/23/2021 |
| Vasopressin in circadian function of SCN. | Vasopressin in circadian function of SCN.
Reghunandanan V. | 10/2/2021 |
| Vasoactive Intestinal Peptide-Secreting Tumors: A Review. | Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS. | 10/3/2020 |
| The plasma levels of VIP observed in gastric cancer group were lower than in colorectal cancer patients (p = 0.01). | Changes in plasma levels of cholecystokinin, neurotensin, VIP and PYY in gastric and colorectal cancer - Preliminary results.
Zygulska AL, Furgala A, Kaszuba-Zwoińska J, Krzemieniecki K, Gil K. | 07/4/2020 |
| Insufficient VIP levels in the microenvironment speeds IL-10 mRNA decay to cause regulatory B cell dysfunction. Administration of VIP can inhibit experimental colitis, suggesting the translational potential of VIP in the treatment of IgE(+) ulcerative colitis. | Vasoactive intestinal peptide stabilizes intestinal immune homeostasis through maintaining interleukin-10 expression in regulatory B cells.
Sun X, Guo C, Zhao F, Zhu J, Xu Y, Liu ZQ, Yang G, Zhang YY, Gu X, Xiao L, Liu Z, Yang PC., Free PMC Article | 06/20/2020 |
| The present data show that low VIP levels result in IL-10 mRNA spontaneously decays in food allergy regulatory B (Br) cells to induce Br cell dysfunction. Administration of VIP restores the immune regulatory function in Br cells, which shows the translational potential for the treatment of food allergy or other allergic diseases. | Vasoactive intestinal peptide alleviates food allergy via restoring regulatory B cell functions.
Zeng HT, Zhao M, Yang SB, Huang H, Geng XR, Liu JQ, Yang G, Li DC, Yang LT, Zheng PY, Yang PC. | 04/25/2020 |
| The results suggest that VIP assists the progress of extravillous trophoblast invasion and vessel remodelling in first-trimester placental bed in an immunologically "silent" milieu. The effects of VIP in the present ex vivo human placental model endorse its potential as a therapeutic candidate for deep placentation disorders. | Vasoactive intestinal peptide shapes first-trimester placenta trophoblast, vascular, and immune cell cooperation.
Paparini DE, Choudhury RH, Vota DM, Karolczak-Bayatti M, Finn-Sell S, Grasso EN, Hauk VC, Ramhorst R, Pérez Leirós C, Aplin JD., Free PMC Article | 04/25/2020 |
| serum vasoactive intestinal peptide levels in postmenopausal osteoporosis patients and the correlation of serum VIP levels with disease severity | The Neuropeptide Vasoactive Intestinal Peptide Levels in Serum are Inversely Related to Disease Severity of Postmenopausal Osteoporosis: A Cross-Sectional Study.
Wang W, Wang ZP, Huang CY, Chen YD, Yao WF, Shi BM. | 12/14/2019 |
| Low VIP expression is associated with acute intussusception. | Serum substance P and vasoactive intestinal peptide levels in infants with acute intussusception.
Zhu ZC, Wang HB, Yan XQ, Yang J, Duan XF, Bian HQ, Kuang HF., Free PMC Article | 12/14/2019 |
| this study shows that VIP is upregulated in women with endometriosis and chronic pelvic pain | Vasoactive intestinal peptide is upregulated in women with endometriosis and chronic pelvic pain.
Bourlev V, Moberg C, Ilyasova N, Davey E, Kunovac Kallak T, Olovsson M. | 11/2/2019 |
| Study shows that mucosal soluble factors from inflammatory bowel diseases induce vasoactive intestinal polypeptide neuroplastic changes in the enteric nervous system. | Modulation of VIPergic phenotype of enteric neurons by colonic biopsy supernatants from patients with inflammatory bowel diseases: Involvement of IL-6 in Crohn's disease.
Soufflet F, Biraud M, Rolli-Derkinderen M, Lardeux B, Trang C, Coron E, Bruley des Varannes S, Bourreille A, Neunlist M. | 10/26/2019 |
| VIP SNPs are associated with VIP serum level and response to rheumatoid arthritis treatment. | Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.
Seoane IV, Martínez C, García-Vicuña R, Ortiz AM, Juarranz Y, Talayero VC, González-Álvaro I, Gomariz RP, Lamana A., Free PMC Article | 12/1/2018 |
| this review provides an overview of VIP effects on rheumatoid arthritis pathology | The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis.
Villanueva-Romero R, Gutiérrez-Cañas I, Carrión M, Pérez-García S, Seoane IV, Martínez C, Gomariz RP, Juarranz Y., Free PMC Article | 10/27/2018 |
| Results have suggested that pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP), but predominantly VIP, induce neuroblastoma differentiation into benign form by regulating hypoxia-inducible factors, vascular endothelial growth factor and vascular endothelial growth factor receptor expression and distribution. | PACAP and VIP regulate hypoxia-inducible factors in neuroblastoma cells exposed to hypoxia.
Maugeri G, D'Amico AG, Rasà DM, Saccone S, Federico C, Cavallaro S, D'Agata V. | 09/29/2018 |
| Results found that VIP enhanced trophoblast cell migration and invasion through the activation of high affinity VPAC receptors and PKA-CRE signaling pathways suggesting that VIP-mediated autocrine pathways regulate trophoblast cell function and contribute to immune homeostasis maintenance at placentation. | Vasoactive Intestinal Peptide modulates trophoblast-derived cell line function and interaction with phagocytic cells through autocrine pathways.
Vota D, Paparini D, Hauk V, Toro A, Merech F, Varone C, Ramhorst R, Pérez Leirós C., Free PMC Article | 04/28/2018 |
| this study shows that that VIP exerts anti-inflammatory effects by inhibiting the MAPK-p47phox phosphorylation-NOX2 activation axis, and that VIP dampens carrageenan-induced inflammation in rats | Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47(phox) phosphorylation pathway in monocytes.
Chedid P, Boussetta T, Dang PM, Belambri SA, Marzaioli V, Fasseau M, Walker F, Couvineau A, El-Benna J, Marie JC. | 11/11/2017 |
| Both mast cells and VIP appear to be important factors in the regulation of this bacterial translocation through the colonic mucosa of irritable bowel syndrome patients. | Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.
Bednarska O, Walter SA, Casado-Bedmar M, Ström M, Salvo-Romero E, Vicario M, Mayer EA, Keita ÅV., Free PMC Article | 10/21/2017 |
| we found that VIP inhibits NFAT nuclear translocation in primary human pulmonary artery smooth muscle cells (PASMC). Early activation of NFATc3 in IPF patients may contribute to disease progression and the increase in VIP expression could be a protective compensatory mechanism | NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.
Szema AM, Forsyth E, Ying B, Hamidi SA, Chen JJ, Hwang S, Li JC, Sabatini Dwyer D, Ramiro-Diaz JM, Giermakowska W, Gonzalez Bosc LV., Free PMC Article | 08/19/2017 |
| VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts. | VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.
Pérez-García S, Carrión M, Gutiérrez-Cañas I, González-Álvaro I, Gomariz RP, Juarranz Y., Free PMC Article | 01/14/2017 |